InsiderTrades.com logo
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
From Weiss Ratings   |   Ad
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Learn these 4 simple steps and protect your savings before it’s too late.
Annette North net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Annette North Biography and Net Worth

EVP of Turning Point Therapeutics
Annette North joined Turning Point Therapeutics in April 2019 as executive vice president and general counsel. Ms. North also serves as company secretary. She brings more than 25 years of experience serving biotechnology companies from inception through private and public financings, business development and acquisitions. Ms. North previously served as a senior executive and general counsel for Kura Oncology and Wellspring Biosciences. Prior to Kura, Ms. North served as senior vice president and general counsel at Ambit Biosciences from initial public offering through acquisition by Daiichi Sankyo. Prior to Ambit, she served as an independent legal counsel to a number of life sciences companies and held legal roles at SGX Pharmaceuticals, Axys Pharmaceuticals, and Sequana Therapeutics. Ms. North began her career at law firms in Melbourne, Australia and London, England. She earned her Bachelor of Laws and Bachelor of Commerce degrees from Melbourne University in Australia, and is a member of the State Bar of California.

What is Annette North's net worth?

The estimated net worth of Annette North is at least $1.21 million as of February 1st, 2021. Ms. North owns 15,984 shares of Turning Point Therapeutics stock worth more than $1,214,944 as of November 25th. This net worth approximation does not reflect any other assets that Ms. North may own. Learn More about Annette North's net worth.

How do I contact Annette North?

The corporate mailing address for Ms. North and other Turning Point Therapeutics executives is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. Turning Point Therapeutics can also be reached via phone at (858) 926-5251 and via email at [email protected]. Learn More on Annette North's contact information.

Has Annette North been buying or selling shares of Turning Point Therapeutics?

Annette North has not been actively trading shares of Turning Point Therapeutics during the last quarter. Most recently, Annette North sold 10,000 shares of the business's stock in a transaction on Monday, August 30th. The shares were sold at an average price of $80.00, for a transaction totalling $800,000.00. Learn More on Annette North's trading history.

Who are Turning Point Therapeutics' active insiders?

Turning Point Therapeutics' insider roster includes Mark Alles (Director), Brian Baker (SVP), Athena Countouriotis (CEO), Jingrong Cui (Director), Mohammad Hirmand (EVP), Annette North (EVP), Andrew Partridge (EVP), Siegfried Reich (EVP), and Paolo Tombesi (CFO). Learn More on Turning Point Therapeutics' active insiders.

Annette North Insider Trading History at Turning Point Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/30/2021Sell10,000$80.00$800,000.00View SEC Filing Icon  
2/1/2021Sell15,984$123.65$1,976,421.6015,984View SEC Filing Icon  
See Full Table

Annette North Buying and Selling Activity at Turning Point Therapeutics

This chart shows Annette North's buying and selling at Turning Point Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Turning Point Therapeutics Company Overview

Turning Point Therapeutics logo
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $76.01
Low: $76.01
High: $76.01

50 Day Range

MA: $75.83
Low: $74.80
High: $76.01

2 Week Range

Now: $76.01
Low: $23.77
High: $82.20

Volume

4,322 shs

Average Volume

1,137,726 shs

Market Capitalization

$3.81 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
From Weiss Ratings   |   Ad
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Learn these 4 simple steps and protect your savings before it’s too late.